

Oryzon Genomics

Q217 results

ORY-1001 rights back to Oryzon

Roche's decision to discontinue the development of ORY-1001 and return the rights to Oryzon was major recent news. Roche cited portfolio reprioritisation as the reason and that the decision was not driven by data. While this is a setback in business development for Oryzon, in our view, ORY-1001's potential has not been compromised and the company indicated that it will continue developing ORY-1001 for both current indications, acute leukaemia and SCLC, before seeking a new partner for late-stage development. On a more positive note, Oryzon reported positive final Phase I data for ORY-2001, which is now ready for further development in several neurological indications. Our valuation is €295m (vs €312m previously) or €8.6/share.

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/15	7.2	(0.1)	(0.01)	0.0	N/A	N/A
12/16	5.0	(4.7)	(0.17)	0.0	N/A	N/A
12/17e	4.4	(6.4)	(0.20)	0.0	N/A	N/A
12/18e	7.9	(11.0)	(0.32)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Next steps with ORY-1001

The handover process may take several months and during this period Roche will also finalise a dose-finding Phase I study in small cell lung cancer (SCLC) and hand the data over to Oryzon, which is now free to initiate planning for further clinical activities, although it will likely take some time to present updated ORY-1001 development plans. Oryzon also mentioned that around the time ORY-1001 was out-licensed to Roche in April 2014, it was contacted by several other companies interested in epigenetic programmes in oncology. In our view, this suggests that the company could potentially replace Roche with another partner interested in epigenetics and LSD1 inhibition.

Q217 results broadly in line with expectations

Oryzon's Q217 results were broadly in line with our expectations. However, we have revised our R&D cost estimates to reflect Oryzon's plan to conduct proof-of-concept studies with ORY-1001 in acute leukaemia and SCLC. We now assume an R&D spend of €5.8m in 2017 and €13.6m in 2018 (total opex €10.4m and €18.4m in respective years). This, however, may be revised further when Oryzon provides more details about further steps with ORY-1001. Oryzon has a strong cash position and we forecast a cash reach well into 2019 (€37.5m end-Q217 cash; €16.1m net cash).

Valuation: Revised to €295m from €312m

We have revised our risk-adjusted NPV model to reflect Oryzon regaining rights to ORY-1001. While we have made changes to a number of assumptions (see below), the one of the main reasons for the lower valuation is reduced probabilities of success to reflect the partnering uncertainty. However, the additional development of ORY-1001 means that in the future Oryzon could negotiate better licensing terms than those with Roche, which could provide upside to our valuation.

Pharma & biotech

22 August 2017

Price **€2.17**

Market cap **€74m**

Net cash (€m) at end Q217 (including term deposits) 16.1

Shares in issue 34.2m


Free float 50%

Code ORY

Primary exchange Madrid Stock Exchange

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs (0.4) (29.5) (26.4)

Rel (local) 0.2 (26.3) (40.0)

52-week high/low €5.1 €2.1

Business description

Oryzon Genomics is a Spanish biotechnology company focused on developing novel epigenetic compounds. First clinical data with lead compound ORY-1001 have been reported in December 2016, while it is currently undergoing a Phase I clinical trial in SCLC. ORY-2001, which has potential for several neurodegenerative diseases, is finishing Phase I. ORY-3001 is a new preclinical asset.

Next events

Initiation of POC trials with ORY-1001 and ORY-2001 in selected indications 2018

Analyst

Jonas Peciulis +44 (0)20 3077 5728

healthcare@edisongroup.com

[Edison profile page](#)

Oryzon Genomics is a research client of Edison Investment Research Limited

Final Phase I results support ORY-2001's safety

Oryzon's Q217 report described progress with its other two lead drug candidates. ORY-2001 (a dual LSD1/MAOB inhibitor) is being developed for neurodegenerative diseases. We discussed ORY-2001's preclinical data and positive preliminary Phase I results released in March 2017 in detail in our [outlook report](#). The final data released in July 2017 confirmed ORY-2001 safety using selected doses in all patients including the elderly. PK/PD data showed that the drug is able to penetrate the blood-brain barrier and allowed Oryzon to model the long-term administration scheme to be used in subsequent efficacy trials. Oryzon now aims to ramp up the clinical programme and initiate trials in several neurological indications, with the leading ones being multiple sclerosis, Alzheimer's disease and Huntington's disease. ORY-3001 (a selective LSD1 inhibitor) is in advanced preclinical studies in as yet undisclosed, orphan, non-cancer indications and should be ready for filing for the investigational new drug application in 2017.

Valuation

Oryzon indicated they will continue to develop ORY-1001 in the acute leukaemia and SCLC indications and will conduct proof-of-concept studies before seeking a new partner, which is in line with its general strategy to partner with larger companies that are able to invest in large-scale studies. In line with this, we now assume that the company will invest €10m in two studies for both indications over the next two years and will then partner for further development in 2019. We now assume an R&D spend of €5.8m in 2017 and €13.6m in 2018. Going forward, virtually all of Oryzon's revenues will account for the capitalisation of the development costs (Oryzon follows Spanish GAAP). Therefore, higher R&D costs have also prompted us to increase our revenue estimates in 2017 and 2018.

We use the Roche deal as a benchmark and include similar terms in our model in 2019. As a reminder, the deal involved a \$21m upfront payment and near-term milestones, \$435m in development-related milestones, \$90m in sales-related milestones and a tiered royalty rate of up to 15% on global sales. \$235m of development-related milestones could have been triggered by events related to oncology projects, with the rest to non-oncologic indications. Since Roche was free to expand into more oncologic indications, we have assumed that one-third of \$235m and \$90 could have been triggered in the acute leukaemia project and another third in the SCLC project. Therefore, the total amount we use currently is \$238m. Of that we include \$21m in an upfront payment as in the Roche deal, \$113m in development milestones, while the rest can be triggered by achieved sales.

In our view, there is potential for Oryzon to negotiate better terms if the POC data are positive because of additional investments in R&D and the fact that the asset is later stage. On the other hand, finding a partner requires time and business development efforts, and we therefore reduce our success probabilities from 20% to 15% for acute leukaemia and from 12% to 8% for SCLC to reflect the partnering uncertainty. This was likely the main reason behind the share price drop following the Roche news, although it stated that the decision was not data driven. The adjustments led us also to delay the launch date for acute leukaemia and SCLC by one year.

With regards to ORY-2001 development, Oryzon's plans were to initiate proof-of-concept studies in several neurological disorders, with the leading studies being multiple sclerosis (MS) and Alzheimer's disease (AD). We previously included AD and MS in our model and make no changes to our [assumptions](#), as the company indicated that there should not be any changes or delays to these programmes. Given the additional investment in ORY-1001, Oryzon has stated that it could

reprioritise and delay ORY-2001 for other neurological indications and the development of ORY-3001. These projects, however, are early stage and we have not yet included them in our valuation.

We have lowered our rNPV from €312m to €295m or from €9.1/share to €8.6/share. We note that the additional ORY-1001 development could create more value for Oryzon. If the next studies are successful, the company could negotiate higher deal terms than those in the Roche agreement, which is still not reflected in our forecast and therefore provides potential upside.

Exhibit 1: Oryzon rNPV valuation

Product	Indication	Launch	Peak sales* (US\$m)	Value (€m)	Probability (%)	rNPV (€m)	NPV/share (€/share)
ORY-1001	AML	2023	930	231.5	15%	42.0	1.2
ORY-1001	SCLC	2026	570	113.0	8%	19.2	0.6
ORY-2001	AD	2026	4,510	844.0	15%	128.8	3.8
ORY-2001	MS	2027	1,940	374.6	20%	88.8	2.6
Net cash (end-Q217)				16.1	100%	16.1	0.5
Valuation				1,579.2		294.9	8.6

Source: Edison Investment Research. Note: *Peak sales are rounded to the nearest US\$10m, shown in US\$. SCLC = small cell lung cancer; AML = acute myeloid leukaemia; AD = Alzheimer's disease; MS = multiple sclerosis. Net cash includes term deposits.

Exhibit 2: Financial summary

December	€000s	2013	2014	2015	2016	2017e	2018e
PROFIT & LOSS		Local GAAP					
Revenue		2,360	15,536	7,185	5,009	4,381	7,906
Cost of Sales		0	0	0	0	0	0
Gross Profit		2,360	15,536	7,185	5,009	4,381	7,906
Research and development		(873)	(1,108)	(3,191)	(5,210)	(5,774)	(13,577)
EBITDA		(94)	11,659	688	(3,721)	(5,024)	(9,681)
Operating Profit (before amort. and except.)		(370)	11,398	448	(3,879)	(5,120)	(9,778)
Intangible Amortisation		(657)	(657)	(657)	(695)	(941)	(1,098)
Exceptionals		(186)	(4,617)	(24)	(4)	0	0
Other		0	0	0	0	0	0
Operating Profit		(1,213)	6,124	(233)	(4,578)	(6,061)	(10,875)
Exceptionals		0	667	(169)	(58)	0	0
Net Interest		(672)	(52)	(553)	(844)	(1,269)	(1,214)
Profit Before Tax (norm)		(1,042)	11,346	(105)	(4,724)	(6,390)	(10,992)
Profit Before Tax (reported)		(1,885)	6,739	(955)	(5,480)	(7,330)	(12,090)
Tax		89	(88)	(37)	32	0	0
Profit After Tax (norm)		(953)	11,258	(142)	(4,692)	(6,390)	(10,992)
Profit After Tax (reported)		(1,796)	6,651	(992)	(5,448)	(7,330)	(12,090)
Average Number of Shares Outstanding (m)		23.0	23.3	24.7	27.6	31.3	34.2
EPS - normalised (EUR)		(0.04)	0.48	(0.01)	(0.17)	(0.20)	(0.32)
EPS - (reported) (EUR)		(0.08)	0.29	(0.04)	(0.20)	(0.23)	(0.35)
Dividend per share (EUR)		0.0	0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		100.0	100.0	100.0	100.0	100.0	100.0
EBITDA Margin (%)		N/A	75.0	9.6	N/A	N/A	N/A
Operating Margin (before GW and except.) (%)		N/A	73.4	6.2	N/A	N/A	N/A
BALANCE SHEET							
Fixed Assets		20,128	16,059	18,050	21,269	24,612	31,324
Intangible Assets		15,825	12,928	15,188	18,810	22,250	29,058
Tangible Assets		1,159	981	854	696	600	503
Investments		3,145	2,150	2,008	1,763	1,763	1,763
Current Assets		2,851	9,999	22,681	28,475	31,573	11,577
Stocks		2	9	4	8	6	7
Debtors		663	704	940	978	959	969
Cash		2,033	3,633	19,467	22,028	29,468	10,601
Other*		153	5,654	2,270	5,461	1,140	0
Current Liabilities		(2,724)	(3,969)	(5,296)	(7,597)	(8,726)	(8,746)
Creditors		(1,005)	(1,299)	(2,401)	(2,119)	(2,080)	(2,100)
Short term borrowings		(1,719)	(2,670)	(2,895)	(5,477)	(6,646)	(6,646)
Long Term Liabilities		(11,251)	(8,196)	(7,841)	(19,419)	(16,478)	(16,478)
Long term borrowings		(9,117)	(6,420)	(6,177)	(17,723)	(14,782)	(14,782)
Other long term liabilities		(2,134)	(1,776)	(1,664)	(1,696)	(1,696)	(1,696)
Net Assets		9,004	13,893	27,594	22,729	30,981	17,677
CASH FLOW							
Operating Cash Flow		(113)	12,178	1,076	(4,536)	(6,311)	(10,887)
Net Interest		(672)	(52)	(553)	(471)	(1,269)	(1,214)
Tax		0	0	0	0	0	0
Capex		0	0	0	(28)	0	0
Acquisitions/disposals		(677)	798	0	0	0	0
Financing		0	0	14,725	287	16,853	0
Other**		(161)	(9,579)	605	(6,819)	(60)	(6,766)
Dividends		0	0	0	0	0	0
Net Cash Flow		(1,623)	3,345	15,853	(11,567)	9,212	(18,867)
Opening net debt/(cash)		7,180	8,803	5,458	(10,395)	1,172	(8,040)
HP finance leases initiated		0	0	0	0	0	0
Other		0	0	0	0	0	0
Closing net debt/(cash)		8,803	5,458	(10,395)	1,172	(8,040)	10,827

Source: Edison Investment Research, Oryzon Genomics accounts. Note: Oryzon reports in Spanish GAAP. *Term deposits classed as other current assets. **Includes cash outflows related to development costs that were capitalised.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Oryzon Genomics and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.